Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis

• Published in: Stem cell research & therapy 2021-05, Vol.12 (1), p.273-273, Article 273
• Main Authors: Li, Yanju, Wang, Feiqing, Liang, Huiling, Tang, Dongxin, Huang, Mei, Zhao, Jianing, Yang, Xu, Liu, Yanqing, Shu, Liping, Wang, Jishi, He, Zhixu, Liu, Yang
• Format: Article
• Language: English
• Subjects: Analysis; Clinical trials; Diabetes; Diabetes mellitus; Diabetes mellitus (insulin dependent); Diabetes mellitus (non-insulin dependent); Diabetes therapy; Fasting; Glucose; Glycosylated hemoglobin; Hemoglobin; Insulin; Insulin resistance; Mesenchymal stem cells; Meta-analysis; Patients; Peptides; Standard deviation; Stem cell transplantation; Stem cells; Transplantation; Transplantation therapy; Type 1 diabetes mellitus; Type 2 diabetes; Type 2 diabetes mellitus
• ISSN: 1757-6512; 1757-6512
• DOI: 10.1186/s13287-021-02342-5

This meta-analysis was first conducted to evaluate the efficacy and safety of transplantation of mesenchymal stem cells in the treatment of type 1 and type 2 diabetes mellitus (T1DM and T2DM). We systematically searched PubMed, ScienceDirect, Google Scholar, CNKI, EMBASE, Web of Science, MEDLINE, and the Cochrane Library for studies published from the establishment of the databases to November 2020. Two researchers independently screened the identified studies, based on inclusion and exclusion criteria. The combined standard mean difference (SMD) and 95% confidence interval (CI) of data from the included studies were calculated using fixed- or random-effects models. We included 10 studies in our meta-analysis (4 studies on T1DM and 6 on T2DM, with 239 participants) to examine the efficacy of mesenchymal stem cells (MSCs) therapy in the treatment of diabetes mellitus. According to the pooled estimates, the glycated hemoglobin (HbA1c) level of the MSC-treated group was significantly lower than it was at baseline (mean difference (MD) = -1.51, 95% CI -2.42 to -0.60, P = 0.001). The fasting C-peptide level of the MSC-treated group with T1DM was higher than that of the control group (SMD = 0.89, 95% CI 0.36 to 1.42, P = 0.001), and their insulin requirement was significantly lower than it was at baseline (SMD = -1.14, 95% CI -1.52 to -0.77, P < 0.00001). Transplantation of mesenchymal stem cells has beneficial effects on diabetes mellitus, especially T1DM, and no obvious adverse reactions.